Capricor Therapeutics Stock Soars 9% After Funding Update — Its Drug Launch Still Awaits Approval
Capricor is preparing an independent launch while cutting roughly 10% of its workforce, even as its quarterly loss widened.
Capricor Therapeutics, which develops cell-based therapies, soared 8.6% to $9.63 in Wednesday trading, as of 9:51 AM ET, adding $44 million in market value after Tuesday's funding update. Without counting potential product sales and other non-operating capital, funding for at least 12 months of company operations was available, the company said in its quarterly SEC filing.
Launch Preparations, Smaller Workforce
Management said on Tuesday's earnings call that it was preparing to launch deramiocel independently. Capricor has cut roughly 10% of its workforce and slowed spending on other programs.
The spending restraint comes with a larger loss. Capricor reported no third-quarter revenue and a net loss of approximately $42.7 million, versus $24.6 million a year earlier.
Capricor Therapeutics Chief Executive Linda Marbán said, “With our San Diego facility operational, we are prepared to move quickly to bring deramiocel to patients, if approved.”
A Narrower Application Awaits The FDA
Deramiocel is Capricor's main treatment candidate, targeting Duchenne muscular dystrophy's heart and skeletal-muscle complications. Clinical development focuses primarily on adolescents and young adults.
The FDA rejected the initial approval application in July 2025 because the evidence of effectiveness was insufficient. In August, Capricor supplied additional two-year trial data and proposed limiting the treatment's use to upper-limb impairment.
That submission prompted a three-month extension of the review. Approval remains pending.
Capricor has no commercially approved products. Collaborations, grants and equity financing support its operations, including upfront and milestone payments from Nippon Shinyaku, deramiocel's exclusive distributor for the United States and Japan. Capricor operates deramiocel manufacturing facilities in San Diego and Los Angeles.
A Rally Within A Steep Slide
Wednesday's gain put the stock on pace for its fifth increase of 7% or more this month. Capricor's market value stood at about $560 million in Wednesday trading.
At Tuesday's close, shares were down 69% year to date, compared with a 10% gain for the S&P 500. They had risen 13% over the previous month.
The FDA's target decision date for deramiocel's Duchenne muscular dystrophy application is November 22.
Sources
- Capricor, NextCure reveal recent layoffs as they gear up for approval decision, merger | Fierce Biotech — fiercebiotech.com
- https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm — sec.gov
- CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review — Yahoo Finance
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision — Yahoo Finance
- Capricor Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- The company's filing (Capricor Therapeutics) — SEC filing
- Capricor Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR